While pan-retinal-photocoagulation, slow-release corticosteroid therapy and anti-vascular endothelial growth factor (anti-VEGF) injections are available, they are used to treat sight-threatening DR but not NPDR, and do not target the underlying disease mechanism [9]. The gene discussed is VEGFA; the disease is non-proliferative diabetic retinopathy.